Humacyte, Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.0M | $0 |
| Cost of Revenue | $9.7M | $0 |
| Gross Profit | $-7.7M | $0 |
| Gross Margin | -376.1% | — |
| Operating Expenses | ||
| Research & Development | $69.3M | $88.6M |
| SG&A Expense | $31.2M | $25.8M |
| Operating Income | $-108.1M | $-114.4M |
| Operating Margin | -5,306.0% | — |
| Interest Expense | — | — |
| Pretax Income | $-40.8M | — |
| Income Tax Expense | $0 | $0 |
| Net Income | $-40.8M | $-148.7M |
| Net Margin | -2,003.6% | — |
| EPS (Basic) | $-0.26 | $-1.26 |
| EPS (Diluted) | $-0.26 | $-1.26 |
| Shares Outstanding (Basic) | 158.2M | 118.5M |
| Shares Outstanding (Diluted) | 158.2M | 118.5M |
| Dividends Per Share | — | — |